Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Ipa2.5
Ipamorelin – Forschung
Überwiegend Mechanismus / Beobachtung
12 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Ipamorelin sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus gemischt-qualitativen randomisierten Studien, veröffentlicht 1998–2024.
Basierend auf 12 Studien · 2 RCTs
Konfidenz
Geringe Konfidenz
Nach Outcome
Growth hormone & body compositionEin selektives GH-Puls-Sekretagogum (tierexperimentelle + humane PK) ohne nachgewiesenen Nutzen beim Menschen; es verfehlte seinen Phase-2-Ileus-Endpunkt. · Nicht etabliert (keine Ergebnisdaten)
Überwiegend Mechanismus / Beobachtung4 Studien
GI motility & postoperative ileus
Überwiegend Mechanismus / Beobachtung3 Studien
Lässt nach
Nur 1 Studie in den letzten 5 Jahren
199820112024
1RCT2014
Beck DE, Sweeney WB, McCarter MD, Beart R · Int J Colorectal Dis (2014)
Einfach gesagt: Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo.
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. · Eur J Endocrinol (1998)
Foundational pharmacology paper that named and characterized ipamorelin as the first selective GH secretagogue
Released GH from primary rat pituitary cells with potency/efficacy similar to GHRP-6
Antagonist profiling showed it acts via a GHRP-like (ghrelin) receptor, not the GHRH receptor
Einfach gesagt: Ipamorelin dose-dependently increased LGR from 42 microm/day in the vehicle group to 44, 50, and 52 microm/day in the treatment groups (P<0.0001).
Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. · Growth Horm IGF Res (1999)
Subcutaneous ipamorelin (18-450 µg/day, 3×/day for 15 days) in adult female rats dose-dependently increased longitudinal bone growth rate and body-weight gain
Notably, treatment did NOT change total IGF-I, IGFBPs, or serum bone-turnover markers
Authors explicitly note that any role in treating growth-retarded children 'requires demonstration in future clinical studies'
Einfach gesagt: By a rational approach we were able to reduce the size of the lead compound ipamorelin and simultaneously to reduce hydrogen-bonding potential ... while retaining in vivo potency in swine.
Hansen TK, Ankersen M, Hansen BS, Raun K, Nielsen KK, Lau J, Peschke B, Lundt BF, Thøgersen H, Johansen NL, Madsen K, Andersen PH. · J Med Chem (1998)
Medicinal-chemistry program using ipamorelin as the lead compound to design orally active GH secretagogues
Screened in a rat pituitary assay and tested for in-vivo potency in swine and oral bioavailability in dogs
Most analogues showed 10-55% oral bioavailability; most potent compound ED50 ~30 nmol/kg IV in swine
Einfach gesagt: Repetitive dosing of ipamorelin (0.1 or 1 mg/kg) significantly increased the cumulative fecal pellet output, food intake, and body weight gain.
Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. · J Pharmacol Exp Ther (2009)
Rat postoperative-ileus model: IV ipamorelin accelerated time to first bowel movement after laparotomy/intestinal manipulation
A single dose shortened time to first bowel movement but did not change cumulative output/food intake; repeated dosing did improve those measures
Provided the preclinical rationale that led to the human postoperative-ileus trials
Einfach gesagt: Anamorelin and ipamorelin administered i.p. had beneficial effects in alleviating cisplatin-induced weight loss during delayed phase.
Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA. · Physiol Behav (2024)
Ferret model of cisplatin chemotherapy: intraperitoneal ipamorelin (1-3 mg/kg) vs vehicle, dosed before cisplatin and every 24 h
Ipamorelin did not affect acute or delayed emesis but reduced associated cisplatin-induced weight loss in the delayed phase (48-72 h) by ~24%
Ipamorelin also inhibited electrical-field-stimulation-induced contractions of isolated ferret ileum (consistent with its ghrelin-receptor GI activity)
Einfach gesagt: Ipamorelin is a synthetic peptide with GH releasing properties. We wished to study the metabolic effects of Ipamorelin and GH on selected hepatic measures of alpha-amino-nitrogen conversion during steroid-induced catabolism.
Aagaard NK, Grøfte T, Greisen J, Malmlöf K, Johansen PB, Grønbaek H, Ørskov H, Tygstrup N, Vilstrup H. · Growth Horm IGF Res (2009)
Rat model of prednisolone-induced catabolism comparing ipamorelin vs GH on nitrogen balance and hepatic urea synthesis
Probed whether the GH-axis effects of ipamorelin could mitigate steroid-driven nitrogen wasting
Metabolic/anti-catabolic animal pharmacology — not a clinical efficacy study
Einfach gesagt: These data suggest that, at least in the young female rat, the GHS Ipamorelin is able to exert a dynamic control effect on the somatotroph population and on GH hormone content.
Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. · Histol Histopathol (2002)
21-day in-vivo ipamorelin dosing followed by in-vitro analysis of rat pituitary somatotroph cells
Increased the volume density of secretion granules in somatotrophs (vs saline)
Did not change somatotroph cell percentage or the ratio of staining cell types
Einfach gesagt: The acute response to either IPA or growth hormone releasing hormone (GHRH) in terms of plasma GH was not changed [by methylprednisolone].
Malmlöf K, Johansen PB, Haahr PM, Wilken M, Oxlund H. · Growth Horm IGF Res (1999)
Tested ipamorelin's GH-releasing and growth-promoting effects in rats given the glucocorticoid methylprednisolone
Methylprednisolone reduced body-weight gain but did not blunt the acute GH response to ipamorelin or GHRH
Explored ipamorelin as a potential counter to steroid-induced catabolism — animal model
Einfach gesagt: Ipamorelin (0.014 µmol/kg intravenous) resulted in a significant acceleration of gastric emptying ... through the stimulation of gastric contractility by activating a ghrelin receptor-mediated mechanism involving cholinergic excitatory neurons.
Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. · J Exp Pharmacol (2012)
Rat gastroparesis/postoperative-ileus model: IV ipamorelin accelerated delayed gastric emptying after abdominal surgery
Reversed the surgery-induced inhibition of acetylcholine- and field-stimulation-induced gastric smooth-muscle contraction in isolated tissue
Identified a ghrelin-receptor + cholinergic-excitatory-neuron mechanism for the prokinetic effect